We are a team of passionate scientists, doctors and clinicians, driven to fight late stage cancers.
About our company, our mission and our team.
Overview of our pipeline and our science
Latest news releases and investor packages
Our pipeline consists of a promising family of small molecules inhibitors of proteins responsible for unconstrained proliferation signaling and metastasis.
Pancreatic Ductal Adenocarcinoma
ANV221 was awarded orphan drug designation for pancreatic cancer based on superiority over gemcitabine and paclitaxel, and disappearing pancreatic cancer tumors with only two weeks of treatment in vivo.
Advanced, Drug-resistant HER2-Positive Breast Cancer
ANV221 reverses tumor growth superior to trastuzumab in advanced, HER2-positive breast cancer in vivo and improves trastuzumab efficacy by up to 90% in drug resistant cell lines.
